Home Cart Sign in  
Chemical Structure| 1449240-68-9 Chemical Structure| 1449240-68-9

Structure of K145 HCl
CAS No.: 1449240-68-9

Chemical Structure| 1449240-68-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

K145 HCl is a selective SphK2 inhibitor with an IC50 of 4.30±0.06 μM , while no inhibition of SphK1 at concentrations up to 10 μM.

Synonyms: K145 (hydrochloride); K145 hydrochloride

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of K145 HCl

CAS No. :1449240-68-9
Formula : C18H25ClN2O3S
M.W : 384.92
SMILES Code : O=C(N(CCN)C/1=O)SC1=C/CCC2=CC=C(OCCCC)C=C2.[H]Cl
Synonyms :
K145 (hydrochloride); K145 hydrochloride
MDL No. :MFCD28160629
InChI Key :HADFDMGQKBGVAV-NKBLJONXSA-N
Pubchem ID :76849910

Safety of K145 HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
A172 5 µM 24 hours K145 significantly inhibited TRIM22 overexpression-induced proliferation of GBM cells PMC10318069
U251MG 5 µM 24 hours K145 significantly inhibited TRIM22 overexpression-induced proliferation of GBM cells PMC10318069
MCF-7 cells 1 µM 2 days K-145 reduced nuclear S1P, almost completely blocked H3-K9ac, HIF1α associated spheroid formation, and enhanced dead cells PMC10112293
HEK cells 50 nM to 1 μM To evaluate the effect of the α V188M mutation on AChR activation kinetics, results showed that the mutation significantly reduced the channel opening rate and gating efficiency. PMC3386830

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NOD/SCID/IL-2Rγ−/− (NSG) mice 5TGM1.BR myeloma model Intraperitoneal injection 20mg/kg K145 and 0.5mg/kg bortezomib K145 six days a week, bortezomib three times a week for 17 days Evaluate combination therapy of K145 with bortezomib PMC8626806
NSG mice TNBC MDA-MB-231 xenograft model Intraperitoneal injection 30 mg/Kg 35 days In the K-145 treatment group, the mean volume of the MDA-MB-231 tumors in the treated mice had a reduced tumor volume >50% compared to vehicle-treated mice. Tumor weights of K-145-treated mice were also significantly less than that of vehicle-treated mice. S1P and dihydro-S1P levels in the tumor tissue nuclei were significantly reduced in the treated group compared to the vehicle group. H3-K9ac, HIF-1α, and HIF-2α levels were decreased in the K145-treated tumor samples compared to the vehicle controls. K145-treated tumors have significantly decreased HIFα-target genes VEGFA and SERPINE1 mRNA compared to the vehicle controls PMC10112293
NOD/SCID mice GBM xenograft model Intraperitoneal injection 50 mg/kg Once daily until the end of the experiment K145 significantly inhibited TRIM22 overexpression-induced proliferation of GBM cells and increased the survival rate of mice PMC10318069

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.60mL

0.52mL

0.26mL

12.99mL

2.60mL

1.30mL

25.98mL

5.20mL

2.60mL

References

 

Historical Records

Categories